Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection

Marcel E. Curlin, Timothy A. Bates, Gaelen Guzman, Devin Schoen, Savannah K. McBride, Samuel D. Carpenter, View ORCID ProfileFikadu G. Tafesse
doi: https://doi.org/10.1101/2022.04.11.22273694
Marcel E. Curlin
1Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: curlin@ohsu.edu tafesse@ohsu.edu
Timothy A. Bates
2Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, Oregon, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaelen Guzman
2Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, Oregon, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devin Schoen
1Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savannah K. McBride
2Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, Oregon, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel D. Carpenter
3Department of Psychiatry, Oregon Health & Science University; Portland, Oregon, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fikadu G. Tafesse
2Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, Oregon, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fikadu G. Tafesse
  • For correspondence: curlin@ohsu.edu tafesse@ohsu.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

The rapid spread of the vaccine-resistant Omicron variant of SARS-CoV-2 presents a renewed threat to both unvaccinated and fully vaccinated individuals, and accelerated booster vaccination campaigns are underway to mitigate the ongoing wave of Omicron cases. The degree of immunity provided by standard vaccine regimens, boosted regimens, and immune responses elicited by the combination of vaccination and natural infection remain incompletely understood. The relative magnitude, quality and durability of serological responses, and the likelihood of neutralizing protection against future SARS-CoV-2 variants following these modes of exposure are unknown but are critical to the future trajectory of the COVID-19 pandemic. In this study of 99 vaccinated adults, we find that compared with responses after two doses of an mRNA regimen, the immune responses three months after a third vaccine dose and one month after breakthrough infection due to prior variants show dramatic increases in magnitude, potency, and breadth, including increased antibody dependent cellular phagocytosis and robust neutralization of the recently circulating Omicron variant. These results suggest that as the number of Omicron cases rise and as global vaccination and booster campaigns continue, an increasing proportion of the world’s population will acquire potent immune responses that may be protective against future SARS-CoV-2 variants.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by a grant from the M. J. Murdock Charitable Trust (to M.E.C.), an unrestricted grant from the OHSU Foundation (to M.E.C.), NIH training grant T32HL083808 (to T.A.B.), and OHSU Innovative IDEA grant 1018784 (to F.G.T.). The funders had no role in the conceptualization, conduct or interpretation of this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Oregon Health and Sciences University Institutional review board gave ethical approval for this work (IRB#00022511).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 12, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection
Marcel E. Curlin, Timothy A. Bates, Gaelen Guzman, Devin Schoen, Savannah K. McBride, Samuel D. Carpenter, Fikadu G. Tafesse
medRxiv 2022.04.11.22273694; doi: https://doi.org/10.1101/2022.04.11.22273694
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection
Marcel E. Curlin, Timothy A. Bates, Gaelen Guzman, Devin Schoen, Savannah K. McBride, Samuel D. Carpenter, Fikadu G. Tafesse
medRxiv 2022.04.11.22273694; doi: https://doi.org/10.1101/2022.04.11.22273694

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (423)
  • Anesthesia (97)
  • Cardiovascular Medicine (902)
  • Dentistry and Oral Medicine (172)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (408)
  • Epidemiology (8810)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1871)
  • Geriatric Medicine (179)
  • Health Economics (389)
  • Health Informatics (1294)
  • Health Policy (644)
  • Health Systems and Quality Improvement (495)
  • Hematology (207)
  • HIV/AIDS (397)
  • Infectious Diseases (except HIV/AIDS) (10593)
  • Intensive Care and Critical Care Medicine (565)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1770)
  • Nursing (105)
  • Nutrition (267)
  • Obstetrics and Gynecology (344)
  • Occupational and Environmental Health (461)
  • Oncology (968)
  • Ophthalmology (285)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (560)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1847)
  • Public and Global Health (3998)
  • Radiology and Imaging (657)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (538)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (167)
  • Surgery (199)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)